✦ LIBER ✦

Quality of life of patients and medical cost of “half elemental diet” as maintenance therapy for Crohn’s disease: Secondary outcomes of a randomised controlled trial

✍ Scribed by S. Takagi; K. Utsunomiya; S. Kuriyama; H. Yokoyama; S. Takahashi; K. Umemura; M. Iwabuchi; H. Takahashi; S. Takahashi; Y. Kinouchi; N. Hiwatashi; Y. Funayama; I. Sasaki; I. Tsuji; T. Shimosegawa

Book ID: 119229293
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 137 KB
Volume: 41
Category: Article
ISSN: 1590-8658
DOI: 10.1016/j.dld.2008.09.007

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effectiveness of an ‘half elemental diet

Effectiveness of an ‘half elemental diet’ as maintenance therapy for Crohn's disease: a randomized-controlled trial

✍ S. TAKAGI; K. UTSUNOMIYA; S. KURIYAMA; H. YOKOYAMA; S. TAKAHASHI; M. IWABUCHI; H 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB

Adherence therapy improves medication ad

Adherence therapy improves medication adherence and quality of life in people with Parkinson's disease: a randomised controlled trial

✍ Daley, D. J.; Deane, K. H. O.; Gray, R. J.; Clark, A. B; Pfeil, M.; Sabanathan, 📂 Article 📅 2014 🏛 John Wiley and Sons 🌐 English ⚖ 170 KB

Cost analysis and quality of life assess

Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma or Hodgkin's disease: a prospective randomised trial

✍ M van Agthoven; E Vellenga; W.E Fibbe; T Kingma; C.A Uyl-de Groot 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 159 KB

143 Welcome: A Randomized, Double-Blind,

143 Welcome: A Randomized, Double-Blind, Controlled Trial Comparing Certolizumab Pegol 400 Mg Every 2 Weeks with Every 4 Weeks for Maintenance of Response and Remission in Patients with Moderate to Severe Crohn's Disease with Secondary Failure to Infliximab

✍ William J. Sandborn; Severine Vermeire; Geert R. D'Haens; Jean-Frederic Colombel 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 102 KB

13 - WELCOME: A randomized, double-blind

13 - WELCOME: A randomized, double-blind, controlled trial comparing certolizumab pegol 400mg every 2 weeks with every 4 weeks for maintenance of response and remission in patients with moderate-to-severe Crohn's disease with secondary failure to infliximab

✍ W.J. Sandborn; S. Vermeire; G. D'Haens; J.F. Colombel; R.N. Fedorak; M.E. Spehlm 📂 Article 📅 2009 🏛 Oxford University Press 🌐 English ⚖ 62 KB